

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Both T and NK Cells

Cell

175, 1731-1743.e13

DOI: [10.1016/j.cell.2018.10.014](https://doi.org/10.1016/j.cell.2018.10.014)

Citation Report

#	ARTICLE	IF	CITATIONS
2	NKG2A Blockade Potentiates CD8 ⁺ Cell Immunity Induced by Cancer Vaccines. <i>Cell</i> , 2018, 175, 1744-1755.e15.	13.5	241
3	NKG2A, a New Kid on the Immune Checkpoint Block. <i>Cell</i> , 2018, 175, 1720-1722.	13.5	83
4	Different Features of Tumor-Associated NK Cells in Patients With Low-Grade or High-Grade Peritoneal Carcinomatosis. <i>Frontiers in Immunology</i> , 2019, 10, 1963.	2.2	21
5	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
6	Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9. <i>Immunology</i> , 2019, 158, 63-69.	2.0	45
7	Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors. <i>Cancers</i> , 2019, 11, 1040.	1.7	40
8	Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 746.	1.6	50
9	Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. <i>Drug Resistance Updates</i> , 2019, 45, 13-29.	6.5	82
10	Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. <i>Frontiers in Immunology</i> , 2019, 10, 1179.	2.2	269
11	NK Cell-Based Immunotherapy for Hematological Malignancies. <i>Journal of Clinical Medicine</i> , 2019, 8, 1702.	1.0	54
12	Artificial Natural Killer Cells for Specific Tumor Inhibition and Renegade Macrophage Re-Education. <i>Advanced Materials</i> , 2019, 31, e1904495.	11.1	59
13	The Good and the Bad of Natural Killer Cells in Virus Control: Perspective for Anti-HBV Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5080.	1.8	39
14	NK Cell-Fc Receptors Advance Tumor Immunotherapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1667.	1.0	17
15	Mobilizing unconventional T cells. <i>Science</i> , 2019, 366, 302-303.	6.0	20
16	Monalizumab: inhibiting the novel immune checkpoint NKG2A. , 2019, 7, 263.		182
17	NK Cell Metabolism and Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 2278.	2.2	264
18	Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1254.	1.6	21
19	Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside. <i>Cancer Immunology Research</i> , 2019, 7, 1742-1747.	1.6	37

#	ARTICLE	IF	CITATIONS
20	The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2354.	2.2	70
21	Exploiting NK Cell Surveillance Pathways for Cancer Therapy. <i>Cancers</i> , 2019, 11, 55.	1.7	41
22	Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1782.	2.2	45
23	The Cynomolgus Macaque MHC Polymorphism in Experimental Medicine. <i>Cells</i> , 2019, 8, 978.	1.8	25
24	Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response. <i>Cancers</i> , 2019, 11, 1217.	1.7	36
25	A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1850.	2.2	21
26	NK Cell Dysfunction and Checkpoint Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1999.	2.2	105
27	Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4315.	1.8	21
28	Natural killer cells and cancer therapy, what we know and where we are going. <i>Immunotherapy</i> , 2019, 11, 1231-1251.	1.0	8
29	Innate lymphoid cells and cancer at border surfaces with the environment. <i>Seminars in Immunology</i> , 2019, 41, 101278.	2.7	11
30	Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. <i>Experimental Hematology and Oncology</i> , 2019, 8, 19.	2.0	30
31	The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers. <i>Current Oncology Reports</i> , 2019, 21, 93.	1.8	16
32	<i>Echinococcus multilocularis</i> inoculation induces NK cell functional decrease through high expression of NKG2A in C57BL/6 mice. <i>BMC Infectious Diseases</i> , 2019, 19, 792.	1.3	12
33	Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 662-675.	8.2	87
34	The innate immune architecture of lung tumors and its implication in disease progression. <i>Journal of Pathology</i> , 2019, 247, 589-605.	2.1	32
35	Negative regulation of innate lymphoid cell responses in inflammation and cancer. <i>Immunology Letters</i> , 2019, 215, 28-34.	1.1	10
36	Hepatic Natural Killer Cells: Organ-Specific Sentinels of Liver Immune Homeostasis and Physiopathology. <i>Frontiers in Immunology</i> , 2019, 10, 946.	2.2	104
37	Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses. <i>Cancer Immunology Research</i> , 2019, 7, 1293-1306.	1.6	46

#	ARTICLE	IF	CITATIONS
38	PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1242.	2.2	130
39	NK Cells in the Human Lungs. <i>Frontiers in Immunology</i> , 2019, 10, 1263.	2.2	57
40	An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More. <i>Frontiers in Immunology</i> , 2019, 10, 1415.	2.2	57
41	Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA. <i>Cancer Immunology Research</i> , 2019, 7, 1120-1134.	1.6	26
42	Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma. <i>Pharmaceutical Medicine</i> , 2019, 33, 269-289.	1.0	10
43	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. <i>Pharmacological Research</i> , 2019, 145, 104258.	3.1	115
44	Helper-like innate lymphoid cells and cancer immunotherapy. <i>Seminars in Immunology</i> , 2019, 41, 101274.	2.7	25
45	NK cells to cure cancer. <i>Seminars in Immunology</i> , 2019, 41, 101272.	2.7	70
46	The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity in part by regulating c-Myc. <i>Nature Immunology</i> , 2019, 20, 865-878.	7.0	120
47	Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 628.	1.7	51
48	Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions. <i>Frontiers in Immunology</i> , 2019, 10, 910.	2.2	54
49	Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 67-81.	2.0	44
50	Innate lymphoid cells: A potential link between microbiota and immune responses against cancer. <i>Seminars in Immunology</i> , 2019, 41, 101271.	2.7	13
51	Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture). <i>Hla</i> , 2019, 93, 185-194.	0.4	11
52	Immunological and clinical implications of immune checkpoint blockade in human cancer. <i>Archives of Pharmacal Research</i> , 2019, 42, 567-581.	2.7	17
53	Targeting natural killer cells in solid tumors. <i>Cellular and Molecular Immunology</i> , 2019, 16, 415-422.	4.8	166
54	Host tissue determinants of tumour immunity. <i>Nature Reviews Cancer</i> , 2019, 19, 215-227.	12.8	150
55	Circulating CD56bright NK cells inversely correlate with survival of melanoma patients. <i>Scientific Reports</i> , 2019, 9, 4487.	1.6	63

#	ARTICLE	IF	CITATIONS
56	Immunotherapy for head and neck cancers: an update and future perspectives. <i>Immunotherapy</i> , 2019, 11, 561-564.	1.0	4
57	Ex vivo Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 454.	2.2	48
58	The Head and Neck Squamous Cell Carcinoma Microenvironment as a Potential Target for Cancer Therapy. <i>Cancers</i> , 2019, 11, 440.	1.7	43
59	NKG2A is a NK cell exhaustion checkpoint for HCV persistence. <i>Nature Communications</i> , 2019, 10, 1507.	5.8	109
60	Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 890.	1.8	34
61	Adding to the checkpoint blockade armamentarium. <i>Nature Medicine</i> , 2019, 25, 203-205.	15.2	5
62	The NKG2A immune checkpoint – a new direction in cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 277-278.	12.5	75
63	Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. <i>Cellular and Molecular Immunology</i> , 2019, 16, 430-441.	4.8	327
64	Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1909-1915.	1.9	21
65	Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy. <i>Trends in Immunology</i> , 2019, 40, 1078-1081.	2.9	4
66	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2019, 629, xxi-xl.	0.4	1
68	Liver-Mediated Adaptive Immune Tolerance. <i>Frontiers in Immunology</i> , 2019, 10, 2525.	2.2	125
69	Harnessing NK Cells for Cancer Treatment. <i>Frontiers in Immunology</i> , 2019, 10, 2836.	2.2	66
70	Precision medicine in the clinical management of respiratory tract infections including multidrug-resistant tuberculosis. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 233-241.	1.2	8
71	Harnessing innate immunity in cancer therapy. <i>Nature</i> , 2019, 574, 45-56.	13.7	533
72	Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board. <i>Trends in Immunology</i> , 2019, 40, 83-85.	2.9	37
73	Natural killer cell transcriptional control, subsets, receptors and effector function. <i>Immunology</i> , 2019, 156, 109-110.	2.0	1
74	Born to Kill: NK Cells Go to War against Cancer. <i>Trends in Cancer</i> , 2019, 5, 143-145.	3.8	2

#	ARTICLE	IF	CITATIONS
75	The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. Trends in Immunology, 2019, 40, 142-158.	2.9	218
76	Checkpoint ahead " be prepared to stop!. Nature Reviews Cancer, 2019, 19, 61-61.	12.8	0
77	A cytofluorimetric assay to evaluate intracellular cytokine production by NK cells. Methods in Enzymology, 2020, 631, 343-355.	0.4	8
78	The Immune Microenvironment and Cancer Metastasis. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a037424.	2.9	57
79	Tumour-intrinsic resistance to immune checkpoint blockade. Nature Reviews Immunology, 2020, 20, 25-39.	10.6	856
80	The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLA-E/β2m overexpression. Modern Pathology, 2020, 33, 468-482.	2.9	44
81	Evaluation of NK cell cytotoxic activity against malignant cells by the calcein assay. Methods in Enzymology, 2020, 631, 483-495.	0.4	10
82	Tumor-derived exosomes (TDEs): How to avoid the sting in the tail. Medicinal Research Reviews, 2020, 40, 385-412.	5.0	35
83	NK cell-based therapeutics for lung cancer. Expert Opinion on Biological Therapy, 2020, 20, 23-33.	1.4	52
84	Recent progress in supramolecular peptide assemblies as virus mimics for cancer immunotherapy. Biomaterials Science, 2020, 8, 1045-1057.	2.6	20
85	Understanding genetic determinants of resistance to immune checkpoint blockers. Seminars in Cancer Biology, 2020, 65, 123-139.	4.3	9
86	NK cells for cancer immunotherapy. Nature Reviews Drug Discovery, 2020, 19, 200-218.	21.5	709
87	Natural Killer Cell Regulation of B Cell Responses in the Context of Viral Infection. Viral Immunology, 2020, 33, 334-341.	0.6	17
88	Patrolling Monocytes Control NK Cell Expression of Activating and Stimulatory Receptors to Curtail Lung Metastases. Journal of Immunology, 2020, 204, 192-198.	0.4	28
89	New avenues for melanoma immunotherapy: Natural Killer cells?. Scandinavian Journal of Immunology, 2020, 91, e12861.	1.3	13
90	Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer. Frontiers in Immunology, 2020, 11, 584099.	2.2	20
91	Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. , 2020, 8, e001054.		54
92	Harnessing Memory NK Cell to Protect Against COVID-19. Frontiers in Pharmacology, 2020, 11, 1309.	1.6	31

#	ARTICLE	IF	CITATIONS
93	Antibody and antibody fragments for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2020, 328, 395-406.	4.8	63
94	NK cells and ILCs in tumor immunotherapy. <i>Molecular Aspects of Medicine</i> , 2021, 80, 100870.	2.7	134
95	COVID-19 Infection: Concise Review Based on the Immunological Perspective. <i>Immunological Investigations</i> , 2020, , 1-20.	1.0	11
96	NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends. <i>Seminars in Immunology</i> , 2020, 48, 101407.	2.7	31
97	Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies. <i>Seminars in Immunology</i> , 2020, 48, 101417.	2.7	132
98	Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer. <i>Chinese Medical Journal</i> , 2020, 133, 2444-2455.	0.9	7
99	Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7032.	1.8	20
100	The NK cellâ€“cancer cycle: advances and new challenges in NK cellâ€“based immunotherapies. <i>Nature Immunology</i> , 2020, 21, 835-847.	7.0	243
101	Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. , 2020, 8, e000772.		36
102	Myeloma cells induce the accumulation of activated CD94 ^{low} NK cells by cell-to-cell contacts involving CD56 molecules. <i>Blood Advances</i> , 2020, 4, 2297-2307.	2.5	11
103	Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy. <i>Cell Reports</i> , 2020, 32, 107848.	2.9	100
104	Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. <i>Life Sciences</i> , 2020, 257, 118058.	2.0	11
105	<p>Glucometabolic Reprogramming in the Hepatocellular Carcinoma Microenvironment: Cause and Effect</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5957-5974.	0.9	21
106	Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade. <i>Immunity</i> , 2020, 53, 1215-1229.e8.	6.6	131
107	Genetic Variants of the NKG2C/HLA-E Receptorâ€“Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell Lymphoma. <i>Cancers</i> , 2020, 12, 3429.	1.7	5
108	Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E. <i>Human Immunology</i> , 2020, 81, 697-701.	1.2	20
109	Emerging immune checkpoint inhibitors for the treatment of head and neck cancers. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 501-514.	1.0	7
110	Multidimensional molecular controls defining NK/ILC1 identity in cancers. <i>Seminars in Immunology</i> , 2021, 52, 101424.	2.7	15

#	ARTICLE	IF	CITATIONS
111	Adoptive natural killer cell therapy: a human pluripotent stem cell perspective. <i>Current Opinion in Chemical Engineering</i> , 2020, 30, 69-76.	3.8	3
112	Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes. <i>Cancers</i> , 2020, 12, 3504.	1.7	30
113	A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 580140.	1.8	10
114	Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. <i>Nature Communications</i> , 2020, 11, 6268.	5.8	206
115	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. <i>Cancers</i> , 2020, 12, 3285.	1.7	85
116	Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer: Her1 and c-Met in Conjunction with the Clinical Features and Human Papillomavirus (p16) Status. <i>Cancers</i> , 2020, 12, 3358.	1.7	5
117	Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells. , 2020, 8, e000515.		27
118	Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors. <i>International Journal of Hematology</i> , 2021, 114, 572-579.	0.7	8
119	Cancer immunotherapy with CAR T cells: many paths ahead of us. <i>Cellular and Molecular Immunology</i> , 2020, 17, 925-939.	4.8	180
120	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3819.	5.8	71
121	The Potential of Five Immune-Related Prognostic Genes to Predict Survival and Response to Immune Checkpoint Inhibitors for Soft Tissue Sarcomas Based on Multi-Omic Study. <i>Frontiers in Oncology</i> , 2020, 10, 1317.	1.3	18
122	The Role of NK Cells and Innate Lymphoid Cells in Brain Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 1549.	2.2	43
123	Make killers sweeter: targeting metabolic checkpoints of NK cells. <i>Nature Immunology</i> , 2020, 21, 970-971.	7.0	1
124	Immunotherapy for squamous cell carcinoma of the head and neck. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1089-1096.	0.6	39
125	Targeting immune checkpoints in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2020, 13, 111.	6.9	66
126	Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8000.	1.8	25
127	Harnessing Natural Killer Cell Function for Genitourinary Cancers. <i>Urologic Clinics of North America</i> , 2020, 47, 433-442.	0.8	6
128	Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 250.	7.1	86

#	ARTICLE	IF	CITATIONS
129	Natural Killer Cells in Immunotherapy: Are We Nearly There?. <i>Cancers</i> , 2020, 12, 3139.	1.7	15
130	Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2-Induced Cytokine Storm. <i>Journal of Immunology</i> , 2020, 205, 2566-2575.	0.4	16
131	Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2691.	1.7	39
132	Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2967.	1.0	23
133	Type 1 Diabetes: Interferons and the Aftermath of Pancreatic Beta-Cell Enteroviral Infection. <i>Microorganisms</i> , 2020, 8, 1419.	1.6	17
134	NK cells beat T cells at early breast cancer control. <i>Oncolmmunology</i> , 2020, 9, 1806010.	2.1	8
135	Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 2156.	2.2	49
136	Covid-19: Perspectives on Innate Immune Evasion. <i>Frontiers in Immunology</i> , 2020, 11, 580641.	2.2	113
137	Diversity Outbred Mice Reveal the Quantitative Trait Locus and Regulatory Cells of HER2 Immunity. <i>Journal of Immunology</i> , 2020, 205, 1554-1563.	0.4	8
138	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. <i>Cancer Discovery</i> , 2020, 10, 1854-1871.	7.7	83
139	Role of the Main Non HLA-Specific Activating NK Receptors in Pancreatic, Colorectal and Gastric Tumors Surveillance. <i>Cancers</i> , 2020, 12, 3705.	1.7	10
140	Epstein-Barr virus peptides derived from latent cycle proteins alter NKG2A+NK cell effector function. <i>Scientific Reports</i> , 2020, 10, 19973.	1.6	16
141	The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 545385.	1.3	14
142	Current Trends in Cancer Immunotherapy. <i>Biomedicines</i> , 2020, 8, 621.	1.4	34
143	Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 575609.	2.2	34
144	Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2. <i>Pathogens</i> , 2020, 9, 1027.	1.2	20
145	Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?. <i>Frontiers in Immunology</i> , 2020, 11, 573662.	2.2	42
146	Tumor-Secreted GRP78 Promotes the Establishment of a Pre-metastatic Niche in the Liver Microenvironment. <i>Frontiers in Immunology</i> , 2020, 11, 584458.	2.2	17

#	ARTICLE	IF	CITATIONS
147	Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. <i>Annals of Translational Medicine</i> , 2020, 8, 1095-1095.	0.7	27
148	Differences of the Immune Phenotype of Breast Cancer Cells after Ex Vivo Hyperthermia by Warm-Water or Microwave Radiation in a Closed-Loop System Alone or in Combination with Radiotherapy. <i>Cancers</i> , 2020, 12, 1082.	1.7	23
149	Clonal expansion of innate and adaptive lymphocytes. <i>Nature Reviews Immunology</i> , 2020, 20, 694-707.	10.6	66
150	Therapeutic ISCOMATRIX [®] adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1959-1972.	2.0	7
151	Can blocking inflammation enhance immunity during aging?. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1323-1331.	1.5	50
152	Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!. <i>Journal of Cellular Physiology</i> , 2020, 235, 9080-9097.	2.0	19
153	Drug repurposing against COVID-19: focus on anticancer agents. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 86.	3.5	57
154	Functional and metabolic targeting of natural killer cells to solid tumors. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 577-600.	2.1	25
155	The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2020, 26, 5549-5556.	3.2	101
156	Dichotomous Regulation of Acquired Immunity by Innate Lymphoid Cells. <i>Cells</i> , 2020, 9, 1193.	1.8	17
157	Harnessing Natural Killer Immunity in Metastatic SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1507-1521.	0.5	50
158	Human cancer germline antigen-specific cytotoxic T cell—what can we learn from patient. <i>Cellular and Molecular Immunology</i> , 2020, 17, 684-692.	4.8	12
159	Consideration of Severe Coronavirus Disease 2019 As Viral Sepsis and Potential Use of Immune Checkpoint Inhibitors. , 2020, 2, e0141.		18
160	IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2371-2380.	2.0	30
161	Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 1295.	2.2	58
162	Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. <i>Frontiers in Immunology</i> , 2020, 11, 1512.	2.2	126
163	The cancer—natural killer cell immunity cycle. <i>Nature Reviews Cancer</i> , 2020, 20, 437-454.	12.8	308
164	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1778-1789.	1.1	34

#	ARTICLE	IF	CITATIONS
165	Innate lymphoid cell and adaptive immune cell cross-talk: A talk meant not to forget. <i>Journal of Leukocyte Biology</i> , 2020, 108, 397-417.	1.5	11
166	Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1455-1489.	1.5	22
167	A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. <i>Cell Research</i> , 2020, 30, 745-762.	5.7	391
168	LPAR1, Correlated With Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 846.	1.3	59
169	Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints. <i>Clinical and Translational Medicine</i> , 2020, 10, 374-411.	1.7	33
170	Regulation of Cancer Immune Checkpoints. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7
171	From cellular microbiology to bacteria-based next generations of cancer immunotherapies. <i>Cellular Microbiology</i> , 2020, 22, e13187.	1.1	3
172	Immune-based therapies for hepatocellular carcinoma. <i>Oncogene</i> , 2020, 39, 3620-3637.	2.6	154
173	miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 119.	1.8	26
174	Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era. <i>International Journal of Cancer</i> , 2020, 147, 1778-1792.	2.3	21
175	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 635, xix-xxxviii.	0.4	0
176	Targeting Natural Killer Cells for Tumor Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 60.	2.2	80
177	Functional exhaustion of antiviral lymphocytes in COVID-19 patients. <i>Cellular and Molecular Immunology</i> , 2020, 17, 533-535.	4.8	1,450
178	You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy. <i>Cancers</i> , 2020, 12, 706.	1.7	73
179	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, xvii-xxxvi.	0.4	0
180	Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies. <i>Blood Reviews</i> , 2020, 44, 100678.	2.8	38
181	Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1391-1401.	2.0	10
182	Immunotherapeutic Potential of TGF- β 2 Inhibition and Oncolytic Viruses. <i>Trends in Immunology</i> , 2020, 41, 406-420.	2.9	55

#	ARTICLE	IF	CITATIONS
183	Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 12022-12028.	7.2	114
184	Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells. <i>Cancer Immunology Research</i> , 2020, 8, 769-780.	1.6	72
185	Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIMmac251 vaginal acquisition. <i>PLoS Pathogens</i> , 2020, 16, e1008377.	2.1	14
186	Targets and Antibody Formats for Immunotherapy of Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1836-1848.	0.8	74
187	Immune Clearance of Senescent Cells to Combat Ageing and Chronic Diseases. <i>Cells</i> , 2020, 9, 671.	1.8	100
188	Pleiotropic Role and Bidirectional Immunomodulation of Innate Lymphoid Cells in Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 3111.	2.2	24
189	NK Cell-Based Immune Checkpoint Inhibition. <i>Frontiers in Immunology</i> , 2020, 11, 167.	2.2	211
190	Boosting Cytotoxic Antibodies against Cancer. <i>Cell</i> , 2020, 180, 822-824.	13.5	3
191	Current progress in NK cell biology and NK cell-based cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 879-899.	2.0	33
192	Cutting Edge: Inhibition of the Interaction of NK Inhibitory Receptors with MHC Class I Augments Antiviral and Antitumor Immunity. <i>Journal of Immunology</i> , 2020, 205, 567-572.	0.4	3
193	Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19. <i>Cellular and Molecular Immunology</i> , 2020, 17, 995-997.	4.8	56
194	A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer. <i>Oncotarget</i> , 2020, 11, 1762473.	2.1	33
195	Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer. <i>Cancers</i> , 2020, 12, 1755.	1.7	37
196	Harnessing NK Cell Checkpoint-Modulating Immunotherapies. <i>Cancers</i> , 2020, 12, 1807.	1.7	17
197	Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	57
198	Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword?. <i>Frontiers in Immunology</i> , 2019, 10, 3140.	2.2	9
199	Unleashing Natural Killer Cells in the Tumor Microenvironment—The Next Generation of Immunotherapy?. <i>Frontiers in Immunology</i> , 2020, 11, 275.	2.2	101
200	Selenium-Containing Nanoparticles Combine the NK Cells Mediated Immunotherapy with Radiotherapy and Chemotherapy. <i>Advanced Materials</i> , 2020, 32, e1907568.	11.1	192

#	ARTICLE	IF	CITATIONS
201	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 631, xxiii-xlii.	0.4	1
202	Two-dimensional dynamic evaluation of natural killer cell-mediated lysis of adherent target cells. <i>Methods in Enzymology</i> , 2020, 631, 289-304.	0.4	0
203	B cells, plasma cells and antibody repertoires in the tumour microenvironment. <i>Nature Reviews Immunology</i> , 2020, 20, 294-307.	10.6	363
204	NK Cell-Based Immunotherapy in Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 316.	1.7	20
205	Exploiting Human NK Cells in Tumor Therapy. <i>Frontiers in Immunology</i> , 2019, 10, 3013.	2.2	37
206	Recalling the Biological Significance of Immune Checkpoints on NK Cells: A Chance to Overcome LAG3, PD1, and CTLA4 Inhibitory Pathways by Adoptive NK Cell Transfer?. <i>Frontiers in Immunology</i> , 2019, 10, 3010.	2.2	48
207	The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy. <i>Cells</i> , 2020, 9, 207.	1.8	38
208	Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin I α 3 in human pancreatic cancer. <i>Scientific Reports</i> , 2020, 10, 537.	1.6	4
209	<p>Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 83-94.	1.0	27
210	Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells. <i>Frontiers in Immunology</i> , 2019, 10, 3026.	2.2	16
211	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 632, xxiii-xlii.	0.4	0
212	CD8+ T Cells Form the Predominant Subset of NKG2A+ Cells in Human Lung Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 3002.	2.2	30
213	Innate Lymphocyte Mechanisms in Skin Diseases. <i>Annual Review of Immunology</i> , 2020, 38, 171-202.	9.5	10
214	Mechanism of tumor cells escaping from immune surveillance of NK cells. <i>Immunopharmacology and Immunotoxicology</i> , 2020, 42, 187-198.	1.1	17
215	Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 545-558.	1.5	9
216	Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells. <i>Cancer Science</i> , 2020, 111, 1478-1490.	1.7	74
217	Lifting the innate immune barriers to antitumor immunity. , 2020, 8, e000695.		50
218	Future Challenges in Cancer Resistance to Immunotherapy. <i>Cancers</i> , 2020, 12, 935.	1.7	41

#	ARTICLE	IF	CITATIONS
219	Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents. <i>Medical Hypotheses</i> , 2020, 140, 109777.	0.8	69
220	Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. <i>British Journal of Pharmacology</i> , 2020, 177, 2889-2903.	2.7	10
221	Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 150, 102966.	2.0	45
222	Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors. <i>Angewandte Chemie</i> , 2020, 132, 12120-12126.	1.6	17
223	Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 475-492.	12.5	80
224	Mechanisms of Resistance to NK Cell Immunotherapy. <i>Cancers</i> , 2020, 12, 893.	1.7	34
225	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. <i>Cancer Treatment Reviews</i> , 2020, 86, 102023.	3.4	34
226	Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 349-360.	1.5	65
227	The unique immune microenvironment of liver metastases: Challenges and opportunities. <i>Seminars in Cancer Biology</i> , 2021, 71, 143-156.	4.3	35
228	Paths taken towards NK cell-mediated immunotherapy of human cancer—a personal reflection. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12993.	1.3	5
229	Non-coding RNA derived from extracellular vesicles in cancer immune escape: Biological functions and potential clinical applications. <i>Cancer Letters</i> , 2021, 501, 234-246.	3.2	20
230	Tumour targetable and microenvironment-responsive nanoparticles simultaneously disrupt the PD-1/PD-L1 pathway and MAPK/ERK/JNK pathway for efficient treatment of colorectal cancer. <i>Journal of Drug Targeting</i> , 2021, 29, 454-465.	2.1	6
231	The role of natural killer cell in gastrointestinal cancer: killer or helper. <i>Oncogene</i> , 2021, 40, 717-730.	2.6	54
232	Decidual-Like NK Cell Polarization: From Cancer Killing to Cancer Nurturing. <i>Cancer Discovery</i> , 2021, 11, 28-33.	7.7	19
233	T Cells: Warriors of SARS-CoV-2 Infection. <i>Trends in Immunology</i> , 2021, 42, 18-30.	2.9	142
234	Tumor-Infiltrating Natural Killer Cells. <i>Cancer Discovery</i> , 2021, 11, 34-44.	7.7	223
235	NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis. <i>Translational Oncology</i> , 2021, 14, 100930.	1.7	95
236	Chimeric antigen receptor (CAR) natural killer (NK) cell therapy: leveraging the power of innate immunity. <i>British Journal of Haematology</i> , 2021, 193, 216-230.	1.2	61

#	ARTICLE	IF	CITATIONS
237	Emerging immunotherapies for metastasis. <i>British Journal of Cancer</i> , 2021, 124, 37-48.	2.9	32
238	Retinoblastoma cell-derived Twist protein promotes regulatory T cell development. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1037-1048.	2.0	1
239	Dual functional nanoparticles efficiently across the blood-brain barrier to combat glioblastoma <i>via</i> simultaneously inhibit the PI3K pathway and NKG2A axis. <i>Journal of Drug Targeting</i> , 2021, 29, 323-335.	2.1	24
240	Tumor-infiltrating lymphocytes in the immunotherapy era. <i>Cellular and Molecular Immunology</i> , 2021, 18, 842-859.	4.8	403
241	Exploring the NK cell platform for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 85-100.	12.5	605
242	Reinvigorating exhausted CD8⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 156-201.	5.0	56
243	Higher-Order Structure Characterization of NKG2A/CD94 Protein Complex and Anti-NKG2A Antibody Binding Epitopes by Mass Spectrometry-Based Protein Footprinting Strategies. <i>Journal of the American Society for Mass Spectrometry</i> , 2021, 32, 1567-1574.	1.2	8
244	Predictive Systems Biomarkers of Response to Immune Checkpoint Inhibitors. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
245	Checkpoint inhibition in the fight against cancer: NK cells have some to say in it. , 2021, , 267-304.		1
246	Role of the Immune Microenvironment in SARS-CoV-2 Infection. <i>Cell Transplantation</i> , 2021, 30, 096368972110106.	1.2	10
247	Challenges for NK cell-based therapies: What can we learn from lymph nodes?. , 2021, , 33-51.		0
248	DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma. <i>International Journal of Biological Sciences</i> , 2021, 17, 3158-3172.	2.6	14
249	Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting. , 2021, 9, e001334.		19
250	Functional Heterogeneity and Therapeutic Targeting of Tissue-Resident Memory T Cells. <i>Cells</i> , 2021, 10, 164.	1.8	9
251	Colon cancer and immunotherapy—can we go beyond microsatellite instability?. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 12-12.	1.5	19
252	Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors. <i>BMB Reports</i> , 2021, 54, 44-58.	1.1	7
253	An immunogenetic view of COVID-19. <i>Genetics and Molecular Biology</i> , 2021, 44, e20210036.	0.6	10
254	Update of Immune Therapies in Recurrent/Metastatic Head and Neck Cancer. , 2021, , 297-306.		0

#	ARTICLE	IF	CITATIONS
255	The SIRP±â€“CD47 immune checkpoint in NK cells. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	82
256	Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis. <i>Immune Network</i> , 2021, 21, e1.	1.6	9
257	NK Cells in Immunotherapy: How Important Are They?. , 2021, , 65-81.		0
258	Immunometabolic targeting of NK cells to solid tumors. , 2021, , 349-368.		0
259	NK cells and CD8 T cells in cancer immunotherapy: Similar functions by different mechanisms. , 2021, , 3-31.		2
260	Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers. <i>Oncolmunology</i> , 2021, 10, 1933808.	2.1	21
261	The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma. , 2021, 5, 304-322.		2
262	A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 316.	1.7	16
263	TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. <i>Oncolmunology</i> , 2021, 10, 1889822.	2.1	21
264	Minimal Residual Disease, Metastasis and Immunity. <i>Biomolecules</i> , 2021, 11, 130.	1.8	21
265	Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response. <i>Oncolmunology</i> , 2021, 10, 1936392.	2.1	14
266	Increased expression of adenosine A3 receptor in tumor-infiltrating natural killer cells. <i>Cellular and Molecular Immunology</i> , 2021, 18, 496-497.	4.8	2
267	Engineered Multifunctional Nanoâ€•and Biological Materials for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001680.	3.9	17
269	The role of donorâ€•unrestricted Tâ€•cells, innate lymphoid cells, and NK cells in antiâ€•mycobacterial immunity. <i>Immunological Reviews</i> , 2021, 301, 30-47.	2.8	20
270	Graft Versus Leukemia: Current Status and Future Perspectives. <i>Journal of Clinical Oncology</i> , 2021, 39, 361-372.	0.8	11
271	A combination of pirfenidone and TGF-Î² inhibition mitigates cystic echinococcosis-associated hepatic injury. <i>Parasitology</i> , 2021, 148, 767-778.	0.7	4
272	Immune checkpoint inhibition in COVID-19: risks and benefits. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1173-1179.	1.4	27
273	Targeting Innate Immunity in Cancer Therapy. <i>Vaccines</i> , 2021, 9, 138.	2.1	57

#	ARTICLE	IF	CITATIONS
274	Killing the Invaders: NK Cell Impact in Tumors and Anti-Tumor Therapy. <i>Cancers</i> , 2021, 13, 595.	1.7	22
275	Metabolism of Innate Immune Cells in Cancer. <i>Cancers</i> , 2021, 13, 904.	1.7	29
276	Quantitative modeling predicts competitive advantages of a next generation anti-CD28 monoclonal antibody over monalizumab for the treatment of cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 220-229.	1.3	3
277	TRIGGERED: could refocused cell signaling be key to natural killer cell-based HIV immunotherapeutics?. <i>Aids</i> , 2021, 35, 165-176.	1.0	4
278	Immune Therapy Resistance and Immune Escape of Tumors. <i>Cancers</i> , 2021, 13, 551.	1.7	32
279	Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 2947-2958.	3.2	24
280	Elevated GAS2L3 Expression Correlates With Poor Prognosis in Patients With Glioma: A Study Based on Bioinformatics and Immunohistochemical Analysis. <i>Frontiers in Genetics</i> , 2021, 12, 649270.	1.1	3
281	HLA-E expression constitutes a novel determinant for ALL disease monitoring following hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1723-1727.	1.3	2
282	Remodeling of Stromal Cells and Immune Landscape in Microenvironment During Tumor Progression. <i>Frontiers in Oncology</i> , 2021, 11, 596798.	1.3	21
284	Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2957-2972.	5.7	34
285	Recent Advancements in Nanomedicine for CAR-T Tumor Immunotherapy. <i>Nano-Micro Letters</i> , 2021, 13, 92.	14.4	41
286	Next generation of immune checkpoint inhibitors and beyond. <i>Journal of Hematology and Oncology</i> , 2021, 14, 45.	6.9	293
288	Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. <i>Cancers</i> , 2021, 13, 1363.	1.7	24
289	Qa-1b Modulates Resistance to Anti-PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing. <i>Molecular Cancer Research</i> , 2021, 19, 1076-1084.	1.5	11
290	Innate Lymphoid Cells and Adaptive Immune Cells Cross-Talk: A Secret Talk Revealed in Immune Homeostasis and Different Inflammatory Conditions. <i>International Reviews of Immunology</i> , 2021, 40, 217-251.	1.5	6
291	In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. <i>Immunity</i> , 2021, 54, 571-585.e6.	6.6	50
292	Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy. <i>Cancers</i> , 2021, 13, 1446.	1.7	12
293	Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 633685.	2.2	4

#	ARTICLE	IF	CITATIONS
294	MHC heterogeneity and response of metastases to immunotherapy. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 501-517.	2.7	12
295	Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 961-974.	1.9	58
296	Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 679117.	2.2	22
297	Natural Killer Cells: From Innate to Adaptive Features. <i>Annual Review of Immunology</i> , 2021, 39, 417-447.	9.5	85
298	HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine. <i>Journal of Hematology and Oncology</i> , 2021, 14, 71.	6.9	11
300	Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies. <i>Cancers</i> , 2021, 13, 1988.	1.7	14
301	Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. <i>Frontiers in Immunology</i> , 2021, 12, 643310.	2.2	27
302	Proliferation of Highly Cytotoxic Human Natural Killer Cells by OX40L Armed NK-92 With Secretory Neoleukin-2/15 for Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 632540.	1.3	8
303	Role and Modulation of NK Cells in Multiple Myeloma. <i>Hemato</i> , 2021, 2, 167-181.	0.2	5
304	Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy. <i>Cells</i> , 2021, 10, 1058.	1.8	17
305	Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. <i>Microbial Cell Factories</i> , 2021, 20, 88.	1.9	37
306	The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. <i>Journal of Translational Medicine</i> , 2021, 19, 142.	1.8	1
307	Differences in the Expression of KIR, ILT Inhibitory Receptors, and VEGF Production in the Induced Decidual NK Cell Cultures of Fertile and RPL Women. <i>BioMed Research International</i> , 2021, 2021, 1-10.	0.9	6
308	Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 172.	3.5	104
309	Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches. <i>Cells</i> , 2021, 10, 1332.	1.8	24
310	The intersection of COVID-19 and cancer: signaling pathways and treatment implications. <i>Molecular Cancer</i> , 2021, 20, 76.	7.9	42
311	Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor. <i>Cancers</i> , 2021, 13, 2673.	1.7	12
312	Immune Responses against Disseminated Tumor Cells. <i>Cancers</i> , 2021, 13, 2515.	1.7	3

#	ARTICLE	IF	CITATIONS
313	Phenotypic and Functional Characteristics of a Novel Influenza Virus Hemagglutinin-Specific Memory NK Cell. <i>Journal of Virology</i> , 2021, 95, .	1.5	8
314	Human NK cells, their receptors and function. <i>European Journal of Immunology</i> , 2021, 51, 1566-1579.	1.6	75
315	The Multifaceted Effects of Breast Cancer on Tumor-Draining Lymph Nodes. <i>American Journal of Pathology</i> , 2021, 191, 1353-1363.	1.9	15
316	Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs. <i>Cancers</i> , 2021, 13, 2500.	1.7	39
317	Characterization and Manipulation of the Crosstalk Between Dendritic and Natural Killer Cells Within the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 670540.	2.2	10
318	MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6741.	1.8	28
319	The prospects of nanotherapeutic approaches for targeting tumor-associated macrophages in oral cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 34, 102371.	1.7	6
320	Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors. <i>Cancers</i> , 2021, 13, 2796.	1.7	13
321	Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy. <i>Cancer Treatment Reviews</i> , 2021, 97, 102192.	3.4	15
322	The CD94/NKG2A inhibitory receptor educates uterine NK cells to optimize pregnancy outcomes in humans and mice. <i>Immunity</i> , 2021, 54, 1231-1244.e4.	6.6	44
323	Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 683381.	2.2	16
324	ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response. <i>Cancers</i> , 2021, 13, 3232.	1.7	15
325	Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms. <i>Cancer Letters</i> , 2021, 507, 55-69.	3.2	53
326	Adaptive Subsets Limit the Anti-Tumoral NK-Cell Activity in Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 1369.	1.8	6
327	Immune Circuits to Shape Natural Killer Cells in Cancer. <i>Cancers</i> , 2021, 13, 3225.	1.7	15
328	Exploring natural killer cell immunology as a therapeutic strategy in lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2788-2805.	1.3	3
329	HLA-G and HLA-E Immune Checkpoints Are Widely Expressed in Ewing Sarcoma but Have Limited Functional Impact on the Effector Functions of Antigen-Specific CAR T Cells. <i>Cancers</i> , 2021, 13, 2857.	1.7	11
330	Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy. <i>Stem Cell Research and Therapy</i> , 2021, 12, 320.	2.4	31

#	ARTICLE	IF	CITATIONS
331	NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6665.	1.8	11
332	Peptide-based assemblies as immune checkpoint inhibitor delivery systems for enhanced immunotherapy. <i>Applied Materials Today</i> , 2021, 23, 101063.	2.3	2
333	Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Cancers</i> , 2021, 13, 3545.	1.7	9
334	Interplay between Neutrophils, NETs and T-Cells in SARS-CoV-2 Infection—A Missing Piece of the Puzzle in the COVID-19 Pathogenesis?. <i>Cells</i> , 2021, 10, 1817.	1.8	8
335	Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. <i>Nature Genetics</i> , 2021, 53, 1196-1206.	9.4	47
336	Leveraging NKG2D Ligands in Immuno-Oncology. <i>Frontiers in Immunology</i> , 2021, 12, 713158.	2.2	56
337	Relevance of Polymorphic KIR and HLA Class I Genes in NK-Cell-Based Immunotherapies for Adult Leukemic Patients. <i>Cancers</i> , 2021, 13, 3767.	1.7	10
338	Inflammation and tumor progression: signaling pathways and targeted intervention. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 263.	7.1	739
339	The Role of Natural Killer Cells in Soft Tissue Sarcoma: Prospects for Immunotherapy. <i>Cancers</i> , 2021, 13, 3865.	1.7	4
340	Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 577-592.	1.6	27
341	Differences in Extracellular Vesicle Protein Cargo Are Dependent on Head and Neck Squamous Cell Carcinoma Cell of Origin and Human Papillomavirus Status. <i>Cancers</i> , 2021, 13, 3714.	1.7	3
343	Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19. <i>Heliyon</i> , 2021, 7, e07635.	1.4	9
344	Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer. <i>Cancers</i> , 2021, 13, 4263.	1.7	32
345	NK cell and ILC heterogeneity in colorectal cancer. New perspectives from high dimensional data. <i>Molecular Aspects of Medicine</i> , 2021, 80, 100967.	2.7	7
346	Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103424.	2.0	19
347	Prognostic value of natural killer cell activity for patients with HER2+ advanced gastric cancer treated with first-line fluoropyrimidine+platinum doublet plus trastuzumab. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 829-838.	2.0	7
348	Interpretable systems biomarkers predict response to immune-checkpoint inhibitors. <i>Patterns</i> , 2021, 2, 100293.	3.1	47
349	The prognostic and clinicopathological roles of microsatellite instability, PD-L1 expression and tumor-infiltrating leukocytes in familial adenomatous polyposis. <i>European Journal of Surgical Oncology</i> , 2022, 48, 211-217.	0.5	0

#	ARTICLE	IF	CITATIONS
350	Deregulation of HLA-I in cancer and its central importance for immunotherapy. , 2021, 9, e002899.		73
351	Peptide Adjuvant to Invigorate Cytolytic Activity of NK Cells in an Obese Mouse Cancer Model. <i>Pharmaceutics</i> , 2021, 13, 1279.	2.0	0
352	Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. <i>Cells</i> , 2021, 10, 2250.	1.8	6
353	Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. <i>Cancer Discovery</i> , 2022, 12, 47-61.	7.7	58
354	Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?. <i>Biomedicines</i> , 2021, 9, 935.	1.4	5
355	Immunosuppressive microenvironment in oral cancer: implications for cancer immunotherapy. <i>Exploration of Immunology</i> , 0, , .	1.7	2
356	NK Cell Therapy: A Rising Star in Cancer Treatment. <i>Cancers</i> , 2021, 13, 4129.	1.7	34
357	Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9044.	1.8	7
358	A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma. <i>Frontiers in Immunology</i> , 2021, 12, 668391.	2.2	25
359	Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy. <i>Applied Materials Today</i> , 2021, 24, 101149.	2.3	7
360	Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model. <i>Frontiers in Pharmacology</i> , 2021, 12, 733075.	1.6	14
361	Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice. <i>Human Immunology</i> , 2022, 83, 86-98.	1.2	37
362	The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 737311.	2.2	28
363	Natural killer cellâ€based immunotherapy for lung cancer: Challenges and perspectives (Review). <i>Oncology Reports</i> , 2021, 46, .	1.2	14
364	Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma. <i>International Immunopharmacology</i> , 2021, 98, 107807.	1.7	13
365	FLT3L Release by Natural Killer Cells Enhances Response to Radioimmunotherapy in Preclinical Models of HNSCC. <i>Clinical Cancer Research</i> , 2021, 27, 6235-6249.	3.2	14
366	Targeting immune dysfunction in aging. <i>Ageing Research Reviews</i> , 2021, 70, 101410.	5.0	76
367	Single-Cell RNA Sequencing Reveals the Heterogeneity of Infiltrating Immune Cell Profiles in the Hepatic Cystic Echinococcosis Microenvironment. <i>Infection and Immunity</i> , 2021, 89, e0029721.	1.0	7

#	ARTICLE	IF	CITATIONS
368	Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: A look into how nanoparticles enhance NK cell activity. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113860.	6.6	31
369	Cellular Immunotherapy and the Lung. <i>Vaccines</i> , 2021, 9, 1018.	2.1	5
370	CENPN Acts as a Novel Biomarker that Correlates With the Malignant Phenotypes of Glioma Cells. <i>Frontiers in Genetics</i> , 2021, 12, 732376.	1.1	12
371	PD-L1 regulation revisited: impact on immunotherapeutic strategies. <i>Trends in Molecular Medicine</i> , 2021, 27, 868-881.	3.5	30
372	Human cytomegalovirus expands a CD8 ⁺ T cell population with loss of <i>BCL11B</i> expression and gain of NK cell identity. <i>Science Immunology</i> , 2021, 6, eabe6968.	5.6	25
373	Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 4722.	1.7	22
374	Combination strategies to maximize the benefits of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 156.	6.9	202
375	Immunobiology of Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 561-576.	0.7	5
376	Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges. <i>Cellular Immunology</i> , 2021, 369, 104436.	1.4	5
377	Natural Killer Cells in Cancer and Cancer Immunotherapy. <i>Cancer Letters</i> , 2021, 520, 233-242.	3.2	19
378	Carbon ion (12C6+) irradiation induces the expression of <i>Klrk1</i> in lung cancer and optimizes the tumor microenvironment based on the NKG2D/NKG2D-Ls pathway. <i>Cancer Letters</i> , 2021, 521, 178-195.	3.2	11
379	Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era. <i>Breast</i> , 2021, 60, 15-25.	0.9	25
380	Targeting natural killer cells in cancer immunotherapy. , 2022, , 63-82.		1
381	Exploiting the CRISPR-Cas9 gene editing system for human cancers and immunotherapy. <i>Clinical and Translational Immunology</i> , 2021, 10, e1286.	1.7	11
382	Employing hypoxia characterization to predict tumour immune microenvironment, treatment sensitivity and prognosis in hepatocellular carcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2775-2789.	1.9	22
383	New therapeutic modalities in breast cancer by targeting NK cell inhibitory and activating receptors. , 2021, , 387-402.		0
384	Natural killer cells in inflammatory autoimmune diseases. <i>Clinical and Translational Immunology</i> , 2021, 10, e1250.	1.7	29
385	Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. <i>Journal of Leukocyte Biology</i> , 2021, 109, 1071-1088.	1.5	25

#	ARTICLE	IF	CITATIONS
386	The Intestinal Tumour Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1226, 1-22.	0.8	10
387	Mechanisms Inspired Targeting Peptides. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 531-546.	0.8	7
388	An integrated multi-omics approach identifies the landscape of interferon- γ -mediated responses of human pancreatic beta cells. <i>Nature Communications</i> , 2020, 11, 2584.	5.8	87
389	Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients. <i>Oncolmmunology</i> , 2021, 10, 1853314.	2.1	24
390	Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response. <i>Oncolmmunology</i> , 2021, 10, 1854529.	2.1	19
392	Programmed cell death 1-expressing CD56-negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment. <i>Cancer Science</i> , 2021, 112, 523-536.	1.7	13
393	Landscape of natural killer cell activity in head and neck squamous cell carcinoma. , 2020, 8, e001523.		36
394	Discovery of specialized NK cell populations infiltrating human melanoma metastases. <i>JCI Insight</i> , 2019, 4, .	2.3	81
395	Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit. <i>JCI Insight</i> , 2020, 5, .	2.3	50
396	Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. <i>Journal of Clinical Investigation</i> , 2019, 129, 2094-2106.	3.9	225
397	Setting traps for NKG2A gives NK cell immunotherapy a fighting chance. <i>Journal of Clinical Investigation</i> , 2019, 129, 1839-1841.	3.9	13
398	Killers 2.0: NK cell therapies at the forefront of cancer control. <i>Journal of Clinical Investigation</i> , 2019, 129, 3499-3510.	3.9	166
399	Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. <i>Journal of Clinical Investigation</i> , 2020, 130, 2560-2569.	3.9	77
400	Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape. <i>Discoveries</i> , 2020, 8, e121.	1.5	15
401	Combinations using checkpoint blockade to overcome resistance. <i>Ecancermedalscience</i> , 2020, 14, 1148.	0.6	11
402	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.	1.2	14
403	Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 3871.	1.7	17
404	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future. <i>Indian Journal of Ophthalmology</i> , 2020, 68, 693.	0.5	78

#	ARTICLE	IF	CITATIONS
405	PRDM1 Drives Human Primary T Cell Hyporesponsiveness by Altering the T Cell Transcriptome and Epigenome. SSRN Electronic Journal, 0, , .	0.4	0
406	Expression Regulation and Function of T-Bet in NK Cells. <i>Frontiers in Immunology</i> , 2021, 12, 761920.	2.2	23
407	The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11385.	1.8	7
408	The Immunology of Hepatocellular Carcinoma. <i>Vaccines</i> , 2021, 9, 1184.	2.1	41
409	NKG2A expression identifies a subset of human V β 2 T β cells exerting the highest antitumor effector functions. <i>Cell Reports</i> , 2021, 37, 109871.	2.9	30
410	NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. <i>Frontiers in Oncology</i> , 2021, 11, 751183.	1.3	10
411	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. <i>European Journal of Cancer</i> , 2021, 158, 17-26.	1.3	33
413	COVID-19: an updated review. <i>Russian Journal of Infection and Immunity</i> , 2020, 10, 247-258.	0.2	2
414	Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor. <i>Cancers</i> , 2021, 13, 5446.	1.7	12
415	<sc>NKG2A</sc> is a late immune checkpoint on <sc>CD8</sc> T cells and marks repeated stimulation and cell division. <i>International Journal of Cancer</i> , 2022, 150, 688-704.	2.3	22
416	Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen. <i>Biological Chemistry</i> , 2021, .	1.2	6
417	NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors. <i>Translational Research</i> , 2022, 240, 64-86.	2.2	11
418	Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 387-407.	2.7	9
420	Quoi de neuf en recherche ?. <i>Annales De Dermatologie Et De Venereologie</i> , 2019, 146, 12S19-12S23.	0.5	0
423	The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer. <i>ChemistrySelect</i> , 2022, 7, 833-866.	0.7	0
424	Crosstalk between macrophages and natural killer cells in the tumor microenvironment. <i>International Immunopharmacology</i> , 2021, 101, 108374.	1.7	23
425	Immunotherapy Approaches in HPV-Associated Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 5889.	1.7	21
426	Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 26-42.	2.0	26

#	ARTICLE	IF	CITATIONS
427	HLA AND CANCER. Physical and Rehabilitation Medicine Medical Rehabilitation, 0, , .	0.1	0
428	Immunesenescence and Compromised Removal of Senescent Cells: Implications for Health in Old Age. Healthy Ageing and Longevity, 2022, , 23-52.	0.2	0
429	An NK-like CAR T cell transition in CAR T cell dysfunction. Cell, 2021, 184, 6081-6100.e26.	13.5	160
430	Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E. Frontiers in Oncology, 2021, 11, 785635.	1.3	9
431	Identification of HIV-Reservoir Cells With Reduced Susceptibility to Antibody-Dependent Immune Response. SSRN Electronic Journal, 0, , .	0.4	0
432	Accounting for B-cell Behavior and Sampling Bias Predicts Anti-PD-L1 Response in Bladder Cancer. Cancer Immunology Research, 2022, 10, 343-353.	1.6	9
433	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomedicine and Pharmacotherapy, 2022, 146, 112516.	2.5	38
435	Monoclonal Antibodies and their Target Specificity Against SARS-CoV-2 Infections: Perspectives and Challenges. Recent Patents on Biotechnology, 2022, 16, 64-78.	0.4	3
436	A Hot Topic: Cancer Immunotherapy and Natural Killer Cells. International Journal of Molecular Sciences, 2022, 23, 797.	1.8	6
437	Downregulated cytotoxic CD8+ T-cell identifies with the NKG2A-soluble HLA-E axis as a predictive biomarker and potential therapeutic target in keloids. Cellular and Molecular Immunology, 2022, 19, 527-539.	4.8	16
438	Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ. Cancer Science, 2022, 113, 864-874.	1.7	8
440	Differential expression of inhibitory receptor NKG2A distinguishes disease-specific exhausted CD8 + T cells. MedComm, 2022, 3, e111.	3.1	2
441	Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. Cell Reports Medicine, 2022, 3, 100508.	3.3	20
442	iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting. Frontiers in Immunology, 2022, 13, 841107.	2.2	42
443	Mechanisms of immune activation and regulation: lessons from melanoma. Nature Reviews Cancer, 2022, 22, 195-207.	12.8	101
444	Identifying and antagonizing the interactions between layilin and glycosylated collagens. Cell Chemical Biology, 2022, 29, 597-604.e7.	2.5	1
445	The War Is on: The Immune System against Glioblastoma—How Can NK Cells Drive This Battle?. Biomedicine, 2022, 10, 400.	1.4	5
446	LLT1-CD161 Interaction in Cancer: Promises and Challenges. Frontiers in Immunology, 2022, 13, 847576.	2.2	15

#	ARTICLE	IF	CITATIONS
447	Selenopeptide Nanomedicine Activates Natural Killer Cells for Enhanced Tumor Chemoimmunotherapy. <i>Advanced Materials</i> , 2022, 34, e2108167.	11.1	32
448	Natural Killer Cell-Mediated Immunotherapy for Leukemia. <i>Cancers</i> , 2022, 14, 843.	1.7	16
449	Senescence and the tumor-immune landscape: Implications for cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2022, 86, 827-845.	4.3	33
450	Perspective of HLA-G Induced Immunosuppression in SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 788769.	2.2	18
451	Natural killer cell-based strategies for immunotherapy of cancer. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, 129, 91-133.	1.0	6
452	Noncoding RNAs as novel immunotherapeutic tools against cancer. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, 129, 135-161.	1.0	3
453	Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma. <i>Current Treatment Options in Oncology</i> , 2022, 23, 210-226.	1.3	7
454	Revealing the transcriptional heterogeneity of organ-specific metastasis in human gastric cancer using single-cell RNA Sequencing. <i>Clinical and Translational Medicine</i> , 2022, 12, e730.	1.7	59
456	Innate lymphoid cells and cancer. <i>Nature Immunology</i> , 2022, 23, 371-379.	7.0	75
458	Simian Immunodeficiency Virus Infection Mediated Changes in Jejunum and Peripheral SARS-CoV-2 Receptor ACE2 and Associated Proteins or Genes in Rhesus Macaques. <i>Frontiers in Immunology</i> , 2022, 13, 835686.	2.2	2
459	Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 62.	3.5	44
460	Tumor Microenvironment and Hydrogel-Based 3D Cancer Models for In Vitro Testing Immunotherapies. <i>Cancers</i> , 2022, 14, 1013.	1.7	17
461	Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. <i>Cancers</i> , 2022, 14, 1189.	1.7	3
462	Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 859177.	2.2	18
463	Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2094-2109.	3.2	60
464	Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies. <i>American Journal of Hematology</i> , 2022, , .	2.0	2
465	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity. <i>Communications Biology</i> , 2022, 5, 271.	2.0	14
466	Dissecting the cellular components of <i>ex vivo</i> $\hat{3}$ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials. <i>Oncolimmunology</i> , 2022, 11, 2057012.	2.1	9

#	ARTICLE	IF	CITATIONS
467	Liver Immunology, Immunotherapy, and Liver Cancers: Time for a Rethink?. <i>Seminars in Liver Disease</i> , 2022, , .	1.8	3
468	The evolutionary legacy of immune checkpoint inhibitors. <i>Seminars in Cancer Biology</i> , 2022, 86, 491-498.	4.3	37
470	Recent advances in nanoscale targeted therapy of HER2-positive breast cancer. <i>Journal of Drug Targeting</i> , 2022, 30, 687-708.	2.1	5
471	The changing role of natural killer cells in cancer metastasis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	36
472	Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. <i>OncImmunology</i> , 2022, 11, 2046931.	2.1	19
473	Antigen presentation by MHC-E: a putative target for vaccination?. <i>Trends in Immunology</i> , 2022, 43, 355-365.	2.9	12
475	Deep phenotyping of surface stimulatory and inhibitory co-receptors on cancer-resident T and NK cells reveals cell subsets within the tumor-reactive CTL population that are uniquely defined by NKG2A expression. <i>SLAS Discovery</i> , 2022, 27, 95-106.	1.4	0
476	Combinatorial Expression of NK Cell Receptors Governs Cell Subset Reactivity and Effector Functions but Not Tumor Specificity. <i>Journal of Immunology</i> , 2022, 208, 1802-1812.	0.4	1
477	COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery. <i>Biomedicines</i> , 2022, 10, 776.	1.4	8
478	Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy. <i>Molecular Immunology</i> , 2022, 144, 58-70.	1.0	23
479	SNAP25 is a potential prognostic biomarker for prostate cancer. <i>Cancer Cell International</i> , 2022, 22, 144.	1.8	9
480	Stemness Subtypes and Scoring System Predict Prognosis and Efficacy of Immunotherapy in Soft Tissue Sarcoma. <i>Frontiers in Immunology</i> , 2022, 13, 796606.	2.2	3
481	Natural killer cell therapy: A new frontier for obesity-associated cancer. <i>Cancer Letters</i> , 2022, 535, 215620.	3.2	17
482	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13311.	1.8	54
483	Challenges of cancer immunotherapy and chemotherapy during the COVID-19 pandemic. <i>Tumori</i> , 2021, , 030089162110639.	0.6	4
484	Central Role of the Antigen-Presentation and Interferon- γ Pathways in Resistance to Immune Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2022, 6, 85-102.	2.3	15
485	Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy. <i>Nature Biomedical Engineering</i> , 2021, 5, 1411-1425.	11.6	96
486	Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment. <i>Cancers</i> , 2021, 13, 6231.	1.7	13

#	ARTICLE	IF	CITATIONS
487	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 509-528.	21.5	201
488	CAR-NK Cells: From Natural Basis to Design for Kill. <i>Frontiers in Immunology</i> , 2021, 12, 707542.	2.2	50
490	Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 164.	1.8	14
491	Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer. <i>Stem Cell Research and Therapy</i> , 2022, 13, 165.	2.4	11
492	SARS-CoV-2 Infection: A Possible Risk Factor for Incidence and Recurrence of Cancers. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 0, , .	0.3	4
493	A NK Cell Odyssey: From Bench to Therapeutics Against Hematological Malignancies. <i>Frontiers in Immunology</i> , 2022, 13, 803995.	2.2	3
494	A Single-Domain TCR-like Antibody Selective for the Qa-1b/Qdm Peptide Complex Enhances Tumoricidal Activity of NK Cells via Blocking the NKG2A Immune Checkpoint. <i>Journal of Immunology</i> , 2022, 208, 2246-2255.	0.4	1
495	Evaluation of HLA-E Expression Combined with Natural Killer Cell Status as a Prognostic Factor for Advanced Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 4951-4960.	0.7	10
496	The tricks for fighting against cancer using CAR NK cells: A review. <i>Molecular and Cellular Probes</i> , 2022, 63, 101817.	0.9	5
512	COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3383-3393.	0.8	120
513	NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. , 2022, 10, e004569.		5
514	Systematic analysis of prognostic significance, functional enrichment and immune implication of STK10 in acute myeloid leukemia. <i>BMC Medical Genomics</i> , 2022, 15, 101.	0.7	3
515	Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
516	NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells. <i>Frontiers in Immunology</i> , 2022, 13, 840844.	2.2	5
517	Immunological microenvironment at the maternal-fetal interface. <i>Journal of Reproductive Immunology</i> , 2022, 151, 103632.	0.8	2
518	PRDM1 Drives Human Primary T Cell Hyporesponsiveness by Altering the T Cell Transcriptome and Epigenome. <i>Frontiers in Immunology</i> , 2022, 13, 879501.	2.2	4
519	Gene knockout in cellular immunotherapy: Application and limitations. <i>Cancer Letters</i> , 2022, 540, 215736.	3.2	10
520	Natural killer cells: unlocking new treatments for bladder cancer. <i>Trends in Cancer</i> , 2022, 8, 698-710.	3.8	5

#	ARTICLE	IF	CITATIONS
521	Tumor-Derived Lactate Creates a Favorable Niche for Tumor via Supplying Energy Source for Tumor and Modulating the Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	14
523	Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment. <i>International Review of Cell and Molecular Biology</i> , 2022, , 65-122.	1.6	4
524	The Promises of Natural Killer Cell Therapy in Endometriosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5539.	1.8	8
527	Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. <i>Nature Reviews Immunology</i> , 2023, 23, 90-105.	10.6	110
528	Turning cold tumors hot: from molecular mechanisms to clinical applications. <i>Trends in Immunology</i> , 2022, 43, 523-545.	2.9	176
529	<sc>NKG2A</sc>â€checkmate inhibition and its blockade critically depends on peptides presented by its ligand <sc>HLAâ€E</sc>. <i>Immunology</i> , 2022, 166, 507-521.	2.0	15
530	CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma. <i>Oncolmmunology</i> , 2022, 11, .	2.1	24
531	Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	5
532	Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response. <i>ELife</i> , 0, 11, .	2.8	10
533	Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
534	Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 673-686.	1.8	3
535	Mechanism of COVID-19 Causing ARDS: Exploring the Possibility of Preventing and Treating SARS-CoV-2. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	19
536	Elevated BCAA Suppresses the Development and Metastasis of Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
537	Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion. <i>JCI Insight</i> , 2022, 7, .	2.3	17
538	Genomic Characteristics, Metabolic Signature and Immune Microenvironment of <i>Clonorchis Sinensis</i>-Related Intrahepatic Cholangiocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
539	NKG2A Expression among CD8 Cells Is Associated with COVID-19 Progression in Hypertensive Patients: Insights from the BRACE CORONA Randomized Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 3713.	1.0	7
540	NK Cell-Based Immunotherapy in Colorectal Cancer. <i>Vaccines</i> , 2022, 10, 1033.	2.1	10
541	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18

#	ARTICLE	IF	CITATIONS
542	Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches. <i>Annals of Oncology</i> , 2022, 33, 893-908.	0.6	29
544	NK cell dysfunction is linked with disease severity in SARS-CoV-2 patients. <i>Cell Biochemistry and Function</i> , 2022, 40, 559-568.	1.4	5
545	Innate immunity as a target for novel therapeutics in triple negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 781-794.	1.9	2
546	Neoantigens and NK Cells: "Trick or Treat" the Cancers?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
547	CD3 ⁺ T Cells in the Tumor Microenvironment "Interactions With Other Immune Cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	30
548	NK Cells and Other Cytotoxic Innate Lymphocytes in Colorectal Cancer Progression and Metastasis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7859.	1.8	10
549	Chip-DSF: A rapid screening strategy for drug protein targets. <i>Pharmacological Research</i> , 2022, 182, 106346.	3.1	3
550	Roles of immune cells in the concurrence of <i>Echinococcus granulosus sensu lato</i> infection and hepatocellular carcinoma. <i>Experimental Parasitology</i> , 2022, 240, 108321.	0.5	0
551	Natural killer cells in antitumour adoptive cell immunotherapy. <i>Nature Reviews Cancer</i> , 2022, 22, 557-575.	12.8	208
552	Immune Checkpoint Inhibitors in Cancer Therapy "How to Overcome Drug Resistance?. <i>Cancers</i> , 2022, 14, 3575.	1.7	18
553	Natural killer cells: the next wave in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
554	Immunosuppressive landscape in hepatocellular carcinoma revealed by single-cell sequencing. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
555	DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells in vitro: a proof-of-concept study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
556	Implications of NKG2A in immunity and immune-mediated diseases. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
557	Shaping the "hot" immunogenic tumor microenvironment by nanoparticles co-delivering oncolytic peptide and TGF- β 1 siRNA for boosting checkpoint blockade therapy. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	5
558	Overcoming tumor resistance mechanisms in CAR-NK cell therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	22
559	XBP1 impacts lung adenocarcinoma progression by promoting plasma cell adaptation to the tumor microenvironment. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
560	The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology. <i>OncImmunology</i> , 2022, 11, .	2.1	4

#	ARTICLE	IF	CITATIONS
561	CAR-NK Cells: A Chimeric Hope or a Promising Therapy?. <i>Cancers</i> , 2022, 14, 3839.	1.7	15
562	Functional crosstalk and regulation of natural killer cells in tumor microenvironment: Significance and potential therapeutic strategies. <i>Genes and Diseases</i> , 2023, 10, 990-1004.	1.5	4
564	Unleashing Anti-Tumor Activity of Natural Killer Cells Via Modulation of Immune Checkpoints Receptors and Molecules. , 0, 8, 463-471.		1
565	New Immuno-oncology Targets and Resistance Mechanisms. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1201-1218.	1.3	10
566	Immune cellular components and signaling pathways in the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2022, 86, 187-201.	4.3	18
567	Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
568	The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. <i>Hepatology</i> , 2023, 77, 1773-1796.	3.6	101
569	Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
570	Minus Times Minus Equals Plus. <i>Journal of Clinical Oncology</i> , 2022, 40, 3453-3455.	0.8	2
571	Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM. <i>EBioMedicine</i> , 2022, 83, 104239.	2.7	11
572	Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer. <i>Cancer Journal (Sudbury, Mass)</i> Tj ETQq0 0 0 rgBT /Overlock 10 1.0 67		
573	A novel cuproptosis-related lncRNA prognostic signature for predicting treatment and immune environment of head and neck squamous cell carcinoma. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 12127-12145.	1.0	0
575	NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. <i>Cancer Cell</i> , 2022, 40, 1027-1043.e9.	7.7	34
576	Induced CD45 Proximity Potentiates Natural Killer Cell Receptor Antagonism. <i>ACS Synthetic Biology</i> , 2022, 11, 3426-3439.	1.9	2
577	KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. <i>Nature Medicine</i> , 2022, 28, 2133-2144.	15.2	50
578	Machine learning identifies exosome features related to hepatocellular carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
579	Bringing natural killer cells to the clinic. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	7
580	Therapeutic strategies for gastric cancer targeting immune cells: Future directions. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12

#	ARTICLE	IF	CITATIONS
581	Dynamic Alteration in HLA-E Expression and Soluble HLA-E via Interaction with Natural Killer Cells in Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2023, 30, 1240-1252.	0.7	3
582	Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. <i>Nature Medicine</i> , 2022, 28, 2155-2161.	15.2	93
583	The soldiers needed to be awakened: Tumor-infiltrating immune cells. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
584	Strategies for Potentiating NK-Mediated Neuroblastoma Surveillance in Autologous or HLA-Haploidentical Hematopoietic Stem Cell Transplants. <i>Cancers</i> , 2022, 14, 4548.	1.7	2
585	Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise?. <i>Cancers</i> , 2022, 14, 4439.	1.7	6
586	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
587	The new progress in cancer immunotherapy. <i>Clinical and Experimental Medicine</i> , 2023, 23, 553-567.	1.9	6
588	In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. <i>Nature Immunology</i> , 2022, 23, 1495-1506.	7.0	57
589	Polymeric Dendrimers as Nanocarrier Vectors for Neurotheranostics. <i>Small</i> , 2022, 18, .	5.2	13
590	Immunotherapy in Head and Neck Cancer When, How, and Why?. <i>Biomedicines</i> , 2022, 10, 2151.	1.4	6
591	Human natural killer cells: Form, function, and development. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 371-385.	1.5	14
592	The prognostic impact of the immune signature in head and neck squamous cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
593	Combination of NKG2A and PD-1 Blockade Improves Radiotherapy Response in Radioresistant Tumors. <i>Journal of Immunology</i> , 2022, 209, 629-640.	0.4	8
594	Beyond PD-1/PD-L1 Immune Checkpoint Inhibitors: Other Targets and Approaches for Head and Neck Cancer. , 2022, , .		0
595	Identification of a novel necroptosis-associated miRNA signature for predicting the prognosis in head and neck squamous cell carcinoma. <i>Open Medicine (Poland)</i> , 2022, 17, 1682-1698.	0.6	2
596	Hypoxia-Regulated Tumor-Derived Exosomes and Tumor Progression: A Focus on Immune Evasion. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11789.	1.8	11
597	Characterization of the SARS-CoV-2 co-receptor NRP1 expression profiles in healthy people and cancer patients: Implication for susceptibility to COVID-19 disease and potential therapeutic strategy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
598	Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 797-804.	2.0	4

#	ARTICLE	IF	CITATIONS
599	Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy. <i>Cancers</i> , 2022, 14, 5046.	1.7	8
600	Impaired intratumoral natural killer cell function in head and neck carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
601	Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity. <i>Cells</i> , 2022, 11, 3147.	1.8	3
602	Uterine NK Cells Ace an "in Education: NKG2A Sets Up Crucial Functions at the Maternal-Fetal Interface. <i>Journal of Immunology</i> , 2022, 209, 1421-1425.	0.4	2
603	Natural killer cell immunotherapy in glioblastoma. <i>Discover Oncology</i> , 2022, 13, .	0.8	8
604	Construction and Validation of a Prognostic Model Based on mRNAi-Related Genes in Breast Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-21.	0.7	2
605	NK cells and solid tumors: therapeutic potential and persisting obstacles. <i>Molecular Cancer</i> , 2022, 21, .	7.9	42
606	Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells. <i>Seminars in Immunology</i> , 2022, 61-64, 101660.	2.7	4
607	The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues. <i>Cancer Letters</i> , 2022, 551, 215947.	3.2	1
608	Weaponizing natural killer cells for solid cancer immunotherapy. <i>Trends in Cancer</i> , 2023, 9, 111-121.	3.8	5
609	Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1153-1167.	2.0	4
613	Gene modified NK cell line as a powerful tool for evaluation of cloned TCRs for TCR-T cell therapy. <i>Cellular Immunology</i> , 2023, 383, 104656.	1.4	1
614	Designing Cancer Immunotherapies That Engage T Cells and NK Cells. <i>Annual Review of Immunology</i> , 2023, 41, 17-38.	9.5	30
615	Detailed phenotypic and functional characterization of CMV-associated adaptive NK cells in rhesus macaques. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
616	Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer. <i>Vaccines</i> , 2022, 10, 1993.	2.1	8
617	Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
618	Allogeneic natural killer cell therapy. <i>Blood</i> , 2023, 141, 856-868.	0.6	33
619	Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15006.	1.8	4

#	ARTICLE	IF	CITATIONS
620	Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
621	The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15907.	1.8	1
622	Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors. <i>Oncolimmunology</i> , 2023, 12, .	2.1	7
623	EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. <i>Science Advances</i> , 2022, 8, .	4.7	14
624	Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5705-5715.	1.2	1
625	Chasing Uterine Cancer with NK Cell-Based Immunotherapies. <i>Future Pharmacology</i> , 2022, 2, 642-659.	0.6	3
626	Prospects for NK-based immunotherapy of chronic HBV infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
627	Releasing the restraints of VÎ³9VÎ²2 T-cells in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
628	Contribution of natural killer cells in innate immunity against colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
629	Tumor-Infiltrating T Cells in EBV-Associated Gastric Carcinomas Exhibit High Levels of Multiple Markers of Activation, Effector Gene Expression, and Exhaustion. <i>Viruses</i> , 2023, 15, 176.	1.5	4
630	Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
631	Mapping the interplay between NK cells and HIV: therapeutic implications. <i>Journal of Leukocyte Biology</i> , 2023, 113, 109-138.	1.5	1
632	Vascular injury is associated with repetitive head impacts and tau pathology in chronic traumatic encephalopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2023, , .	0.9	7
633	The imbalance betweenÂNKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virusâ€related hepatocellular carcinoma. <i>Hepatology Research</i> , 2023, 53, 417-431.	1.8	3
634	Cellular Senescence in Hepatocellular Carcinoma: The Passenger or the Driver?. <i>Cells</i> , 2023, 12, 132.	1.8	5
635	Insights into the tumor microenvironment of B cell lymphoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	8
636	Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. <i>Cancer Communications</i> , 2023, 43, 177-213.	3.7	8
637	Natural Killer Cell-Based Cancer Immunotherapy: From Bench to Bedside. , 0, , .		0

#	ARTICLE	IF	CITATIONS
638	Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382211505.	0.8	7
639	Multifaceted nature of natural killer cells: Potential mode of interaction and shaping of stem cells. , 2023, , 3-25.		1
640	Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
641	Natural killer cells in the treatment of glioblastoma: Diverse antitumor functions and potential clinical applications. , 2023, , 335-367.		1
642	Reversing the NK inhibitory tumor microenvironment by targeting suppressive immune effectors. , 2023, , 27-63.		1
643	Natural killer cells as immunotherapeutic effectors for solid tumors. , 2023, , 65-81.		0
644	Antitumor Immunity Exerted by Natural Killer and Natural Killer T Cells in the Liver. <i>Journal of Clinical Medicine</i> , 2023, 12, 866.	1.0	2
645	Combining radiotherapy and NK cell-based therapies: The time has come. <i>International Review of Cell and Molecular Biology</i> , 2023, , .	1.6	1
646	HLA-E*01:01+HLA-E*01:01 genotype confers less susceptibility to COVID-19, while HLA-E*01:03+HLA-E*01:03 genotype is associated with more severe disease. <i>Human Immunology</i> , 2023, 84, 263-271.	1.2	1
647	Immunotherapy-based combinations in metastatic NSCLC. <i>Cancer Treatment Reviews</i> , 2023, 116, 102545.	3.4	6
648	Natural Killer Cell-Based Immunotherapy against Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2111.	1.8	4
649	Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. <i>Biology</i> , 2023, 12, 218.	1.3	27
650	A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	3
651	Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports. <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 187-200.	1.9	1
652	NKG2A blocks the anti-metastatic functions of natural killer cells. <i>Cancer Cell</i> , 2023, 41, 232-234.	7.7	5
653	Graphdiyne Oxide-Mediated Photodynamic Therapy Boosts Enhance T-Cell Immune Responses by Increasing Cellular Stiffness. <i>International Journal of Nanomedicine</i> , 0, Volume 18, 797-812.	3.3	4
654	Advances in NK cell therapy for brain tumors. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	8
655	OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. <i>Cell Reports Medicine</i> , 2023, 4, 100939.	3.3	6

#	ARTICLE	IF	CITATIONS
656	NKG2A Immune Checkpoint in V α 2 T Cells: Emerging Application in Cancer Immunotherapy. <i>Cancers</i> , 2023, 15, 1264.	1.7	3
657	NK cells are never alone: crosstalk and communication in tumour microenvironments. <i>Molecular Cancer</i> , 2023, 22, .	7.9	19
658	Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	81
659	Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment. <i>Molecular Cancer</i> , 2023, 22, .	7.9	22
660	Killer to cure: Expression and production costs calculation of tobacco plant-made cancer immune checkpoint inhibitors. <i>Plant Biotechnology Journal</i> , 2023, 21, 1254-1269.	4.1	4
661	Increased NKG2A+CD8+ T-cell exhaustion in patients with adenomyosis. <i>Mucosal Immunology</i> , 2023, 16, 121-134.	2.7	1
663	Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 0, , .	1.0	0
664	Human CD8 ⁺ T-Cell Populations That Express Natural Killer Receptors. <i>Immune Network</i> , 2023, 23, .	1.6	10
665	Diversity of immune checkpoints in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	11
666	A knowledge empowered explainable gene ontology fingerprint approach to improve gene functional explication and prediction. <i>IScience</i> , 2023, 26, 106356.	1.9	2
667	Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles. <i>International Journal of Pharmaceutics</i> , 2023, 636, 122810.	2.6	2
668	The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. <i>Cancers</i> , 2023, 15, 1642.	1.7	4
669	Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 630-645.	1.9	1
670	A Nanotherapeutic Strategy to Reverse NK Cell Exhaustion. <i>Advanced Materials</i> , 2023, 35, .	11.1	7
671	Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions (CME article). <i>International Journal of Cancer Care and Delivery</i> , 2023, 3, .	0.0	0
672	An updated review of the immunological mechanisms of keloid scars. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
673	Tumors evade immune cytotoxicity by altering the surface topology of NK cells. <i>Nature Immunology</i> , 2023, 24, 802-813.	7.0	17
674	Emerging Targeted Therapies for HER2-Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 1987.	1.7	18

#	ARTICLE	IF	CITATIONS
675	Assessing the Impact of Persistent HIV Infection on Innate Lymphoid Cells Using In Vitro Models. <i>ImmunoHorizons</i> , 2023, 7, 243-255.	0.8	0
676	Optimizing Drug Therapies in the Maintenance Setting After Radiochemotherapy in Non-small Cell Lung Cancer. <i>Medical Radiology</i> , 2023, , .	0.0	0
677	Preventing the tumor metastasis by blocking the immune checkpoint HLA-E:CD94-NKG2A of circulating tumor cells. <i>Chinese Science Bulletin</i> , 2023, , .	0.4	0
678	COVID-19 immunotherapy: a mathematical model. <i>Mathematical Medicine and Biology</i> , 2023, 40, 199-221.	0.8	1
679	Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. <i>Cancer Reports</i> , 2023, 6, .	0.6	4
680	The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy. <i>Cancers</i> , 2023, 15, 2323.	1.7	14
681	Why does the immune system destroy pancreatic β -cells but not α -cells in type 1 diabetes?. <i>Nature Reviews Endocrinology</i> , 2023, 19, 425-434.	4.3	10
682	Innate lymphoid cells and innate-like T cells in cancer " at the crossroads of innate and adaptive immunity. <i>Nature Reviews Cancer</i> , 2023, 23, 351-371.	12.8	15
730	Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics. <i>Clinical and Experimental Medicine</i> , 2023, 23, 4297-4322.	1.9	2
738	Systemic Oncosphere: Host Innate Immune System. , 2023, , 419-442.		0
744	Current status and frontier tracking of clinical trials on Metformin for cancer treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 16931-16946.	1.2	1
753	Unleashing the Potential of Natural Killer Cells in Immunotherapy for Glioblastoma and Brain Tumors. , 2023, , .		0